Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics–small molecule drug interactions

References

• Evaluate Pharma World Preview 2015, Outlook to 2020. Available from: http://info.evaluategroup.com/rs/evaluatepharmaltd/images/EP240614.pdf.
   Google Scholar
• Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood. 2011 Mar;17(117):2993–3001.
   Web of Science ®Google Scholar
• Lee JI, Zhang L, Men AY, et al. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet. 2010;49:295–310.
   PubMed Web of Science ®Google Scholar
• Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004 Sep;1:24–29.
   PubMedGoogle Scholar
• Dimitrov DS. Therapeutic proteins. Methods Mol Biol. 2012;899:1–26.
   PubMedGoogle Scholar
• Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008 Jan;7:21–39.
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Xu X, Theil FP, et al. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem. 2012 Apr;26(3):73–92.
   Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493–507.
   PubMed Web of Science ®Google Scholar
• Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011 Oct;28:2379–2385.
   PubMed Web of Science ®Google Scholar
• Xu X, Vugmeyster Y. Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. Aaps J. 2012 Dec;14:781–791.
   PubMed Web of Science ®Google Scholar
• Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007 Sep;47:1104–1118.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol. 2007 Dec;47:1540–1554.
   PubMed Web of Science ®Google Scholar
• Yang BB, Gillespie B, Smith B, et al. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin. J Clin Pharmacol. 2015;55:1109–1118.
   Google Scholar
• Dorr RT. Interferon-alpha in malignant and viral diseases. A review. Drugs. 1993;45:177–211.
   Google Scholar
• Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet. 1987 Oct;24(2):939–941.
   Google Scholar
• Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr Drug Abuse Rev. 2008;1:177–187.
   Google Scholar
• Product Information Poryrazza (Necitumumab). Eli Lilly and Company.
   Google Scholar
• Vasquez EM, Pollak R. OKT3 therapy increases cyclosporine blood levels. Clin Transplant. 1997 Feb;11:38–41.
   PubMed Web of Science ®Google Scholar
• Strehlau J, Pape L, Offner G, et al. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet. 2000 Oct 14;356:1327–1328.
   PubMed Web of Science ®Google Scholar
• Furtlehner A, Schueller J, Jarisch I, et al. Disposition of paclitaxel (Taxol) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin). Eur J Drug Metab Pharmacokinet. 2005;30:145–150.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Fleming KF. Interaction between adalimumab with concurrent pregabalin and duloxetine administration in a psoriasis patient with diabetic peripheral neuropathy. Cutis. 2011 May;87:249–250.
   PubMed Web of Science ®Google Scholar
• Velickovic-Radovanovic RM, Paunovic G, Mikov M, et al. Clinical pharmacokinetics of tacrolimus after the first oral administration in renal transplant recipients on triple immunosuppressive therapy. Basic Clin Pharmacol Toxicol. 2010;106:505–510.
   Google Scholar
• Kim S, Ostor AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int. 2012;32:2601–2604.
   Google Scholar
• Okuno H, Takasu M, Kano H, et al. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology. 1993;17:65–69.
   PubMed Web of Science ®Google Scholar
• Kraemer MJ, Furukawa CT, Koup JR, et al. Altered theophylline clearance during an influenza B outbreak. Pediatrics. 1982;69:476–480.
   PubMed Web of Science ®Google Scholar
• Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther. 2005 May-Jun;12:254–261.
   PubMedGoogle Scholar
• Craig PI, Tapner M, Farrell GC. Interferon suppresses erythromycin metabolism in rats and human subjects. Hepatology. 1993 Feb;17:230–235.
   PubMed Web of Science ®Google Scholar
• Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol. 1986 Nov;22:610–612.
   PubMed Web of Science ®Google Scholar
• Brennan BJ, Xu ZX, Grippo JF. Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Br J Clin Pharmacol. 2013 Feb;75:497–506.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, De Vries DE, Xu Z, et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55:1386–1394.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Kuhn B, Zhang X, et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89:735–740.
   PubMed Web of Science ®Google Scholar
• Doi T, Muro K, Yoshino T, et al. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2013;72:643–652.
   PubMed Web of Science ®Google Scholar
• Lee EB, Daskalakis N, Xu C, et al. Disease–drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacokinet. 2016. DOI:10.1007/s40262-016-0462-8
   Google Scholar
• Chang KC, Bell TD, Lauer BA, et al. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet. 1978 May;27(1):1132–1133.
   Google Scholar
• Jones AE, Brown KC, Werner RE, et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol. 2010;66:475–485.
   PubMed Web of Science ®Google Scholar
• Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46:123–149.
   PubMed Web of Science ®Google Scholar
• Zidek Z, Anzenbacher P, Kmonickova E. Current status and challenges of cytokine pharmacology. Br J Pharmacol. 2009 Jun;157:342–361.
   PubMed Web of Science ®Google Scholar
• Siewert E, Bort R, Kluge R, et al. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology. 2000;32:49–55.
   PubMed Web of Science ®Google Scholar
• Ashino T, Oguro T, Shioda S, et al. Involvement of interleukin-6 and tumor necrosis factor alpha in CYP3A11 and 2C29 down-regulation by Bacillus Calmette-Guerin and lipopolysaccharide in mouse liver. Drug Metab Dispos. 2004;32:707–714.
   PubMed Web of Science ®Google Scholar
• Dickmann LJ, Patel SK, Rock DA, et al. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos. 2011;39:1415–1422.
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.Transplantation. 1990;49:697–702.
   PubMed Web of Science ®Google Scholar
• Ramirez CB, Marino IR. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther. 2007;7:137–148.
   Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 Feb;24(124):783–801.
   Web of Science ®Google Scholar
• Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity. 1999;11:443–451.
   PubMed Web of Science ®Google Scholar
• Aliprantis AO, Yang RB, Mark MR, et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science. 1999 Jul 30;285:736–739.
   PubMed Web of Science ®Google Scholar
• Ghose R, Guo T, Vallejo JG, et al. Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes. Drug Metab Dispos. 2011;39:874–881.
   PubMed Web of Science ®Google Scholar
• Ghose R, White D, Guo T, et al. Regulation of hepatic drug-metabolizing enzyme genes by Toll-like receptor 4 signaling is independent of Toll-interleukin 1 receptor domain-containing adaptor protein. Drug Metab Dispos. 2008 Jan;36:95–101.
   PubMed Web of Science ®Google Scholar
• Geddes K, Magalhaes JG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov. 2009 Jun;8:465–479.
   PubMed Web of Science ®Google Scholar
• Zidek Z, Kamenikova L, Buchar E, et al. Biotransformation of drugs in rats treated with a synthetic muramyl dipeptide, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP). Int J Immunopharmacol. 1983;5:151–155.
   PubMed Web of Science ®Google Scholar
• Cantwell CA, Sterneck E, Johnson PF. Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol. 1998 Apr;18:2108–2117.
   PubMed Web of Science ®Google Scholar
• An MR, Hsieh CC, Reisner PD, et al. Evidence for posttranscriptional regulation of C/EBPalpha and C/EBPbeta isoform expression during the lipopolysaccharide-mediated acute-phase response. Mol Cell Biol. 1996 May;16:2295–2306.
   PubMed Web of Science ®Google Scholar
• Baumann H, Morella KK, Campos SP, et al. Role of CAAT-enhancer binding protein isoforms in the cytokine regulation of acute-phase plasma protein genes. J Biol Chem. 1992 Sep;25(267):19744–19751.
   Google Scholar
• Martinez-Jimenez CP, Gomez-Lechon MJ, Castell JV, et al. Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol Pharmacol. 2005;67:2088–2101.
   PubMed Web of Science ®Google Scholar
• Jover R, Bort R, Gomez-Lechon MJ, et al. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. Faseb J. 2002;16:1799–1801.
   PubMed Web of Science ®Google Scholar
• Cheng PY, Wang M, Morgan ET. Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin. J Pharmacol Exp Ther. 2003 Dec;307:1205–1212.
   PubMed Web of Science ®Google Scholar
• Zhou C, Tabb MM, Nelson EL, et al. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest. 2006;116:2280–2289.
   PubMed Web of Science ®Google Scholar
• Gu X, Ke S, Liu D, et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem. 2006 Jun 30;281:17882–17889.
   PubMed Web of Science ®Google Scholar
• Beigneux AP, Moser AH, Shigenaga JK, et al. The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem. 2000 May;26(275):16390–16399.
   Web of Science ®Google Scholar
• Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, et al. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos. 2004;32:20–27.
   PubMed Web of Science ®Google Scholar
• Ghose R, Zimmerman TL, Thevananther S, et al. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept. 2004 Aug;16(2):4.
   Google Scholar
• Kimura A, Naka T, Nakahama T, et al. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med. 2009 Aug 31;206:2027–2035.
   PubMed Web of Science ®Google Scholar
• Wu D, Li W, Lok P, et al. AhR deficiency impairs expression of LPS-induced inflammatory genes in mice. Biochem Biophys Res Commun. 2011 Jul;1(410):358–363.
   Web of Science ®Google Scholar
• Shah YM, Ma X, Morimura K, et al. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1114–22.
   PubMed Web of Science ®Google Scholar
• Sun M, Cui W, Woody SK, et al. Pregnane X receptor modulates the inflammatory response in primary cultures of hepatocytes. Drug Metab Dispos. 2015;43:335–343.
   PubMed Web of Science ®Google Scholar
• Yin S, Cao W. Toll-like receptor signaling induces Nrf2 pathway activation through p62-triggered keap1 degradation. Mol Cell Biol. 2015 Aug;35:2673–2683.
   PubMed Web of Science ®Google Scholar
• Wu KC, Cui JY, Klaassen CD. Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver. PLoS One. 2012;7:e39006.
   PubMed Web of Science ®Google Scholar
• Moriguchi T, Toyoshima F, Masuyama N, et al. A novel SAPK/JNK kinase, MKK7, stimulated by TNFalpha and cellular stresses. Embo J. 1997 Dec 1;16:7045–7053.
   PubMed Web of Science ®Google Scholar
• Ghose R, Guo T, Haque N. Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, lipoteichoic acid. Arch Biochem Biophys. 2009 Jan 1;481:123–130.
   PubMed Web of Science ®Google Scholar
• Yu R, Lei W, Mandlekar S, et al. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J Biol Chem. 1999 Sep;24(274):27545–27552.
   Web of Science ®Google Scholar
• Li D, Zimmerman TL, Thevananther S, et al. Interleukin-1 beta-mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependent. J Biol Chem. 2002 Aug 30;277:31416–31422.
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Dvorak Z, Gerbal-Chaloin S, et al. Pathophysiological factors affecting CAR gene expression. Drug Metab Rev. 2003;35:255–268.
   PubMed Web of Science ®Google Scholar
• Shah P, Omoluabi O, Moorthy B, et al. Role of adaptor protein toll-like interleukin domain containing adaptor inducing interferon beta in toll-like receptor 3- and 4-mediated regulation of hepatic drug metabolizing enzyme and transporter genes. Drug Metab Dispos. 2016;44:61–67.
   PubMed Web of Science ®Google Scholar
• Tili E, Michaille JJ, Cimino A, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunology. 2007 Oct 15;179:5082–5089.
   PubMed Web of Science ®Google Scholar
• Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos. 2009 Oct;37:2112–2117.
   PubMed Web of Science ®Google Scholar
• Ji J, Zhang J, Huang G, et al. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Letters. 2009 Feb 18;583:759–766.
   PubMed Web of Science ®Google Scholar
• Lamba V, Ghodke Y, Guan W, et al. microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450. Biochem Biophys Res Commun. 2014 Mar 7;445:404–411.
   PubMed Web of Science ®Google Scholar
• Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell. 2003 Dec;26(115):787–798.
   Web of Science ®Google Scholar
• Carlson TJ, Billings RE. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450. Mol Pharmacol. 1996 May;49:796–801.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000 Dec;7(408):740–745.
   Google Scholar
• Hennessy EJ, Parker AE, O’Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010 Apr;9:293–307.
   PubMed Web of Science ®Google Scholar
• Cole JE, Mitra AT, Monaco C. Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets. Expert Rev Cardiovasc Ther. 2010 Nov;8:1619–1635.
   PubMedGoogle Scholar
• Funk JL, Feingold KR, Moser AH, et al. Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis. 1993 Jan 4;98:67–82.
   PubMed Web of Science ®Google Scholar
• Oiknine J, Aviram M. Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages. Arterioscler Thromb Vasc Biol. 1992 Jun;12:745–753.
   PubMedGoogle Scholar
• Choi SH, Harkewicz R, Lee JH, et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res. 2009 Jun 19;104:1355–1363.
   PubMed Web of Science ®Google Scholar
• Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005 Nov;115:3149–3156.
   PubMed Web of Science ®Google Scholar
• Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004 Jul 20;101:10679–10684.
   PubMed Web of Science ®Google Scholar
• Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett. 2014 Dec;1(24):5357–5363.
   Web of Science ®Google Scholar
• Seggewiss R, Einsele H. Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation. Semin Hematol. 2007;44:203-211.
   Google Scholar
• Fortin CF, Larbi A, Dupuis G, et al. GM-CSF activates the Jak/STAT pathway to rescue polymorphonuclear neutrophils from spontaneous apoptosis in young but not elderly individuals. Biogerontology. 2007;8:173–187.
   PubMed Web of Science ®Google Scholar
• Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013 May;2(368):1685–1694.
   Web of Science ®Google Scholar
• Taganov KD, Boldin MP, Chang KJ, et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006 Aug 15;103:12481–12486.
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Chaudhuri AA, Rao DS, et al. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A. 2009 Apr 28;106:7113–7118.
   PubMed Web of Science ®Google Scholar
• Pitarque M, Rodriguez-Antona C, Oscarson M, et al. Transcriptional regulation of the human CYP2A6 gene. J Pharmacol Exp Ther. 2005;313:814–822.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Bort R, Jover R, et al. Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. Mol Pharmacol. 2003;63:1180–1189.
   PubMed Web of Science ®Google Scholar